Market Cap (In HKD)
3.05 Billion
Revenue (In HKD)
463.84 Million
Net Income (In HKD)
-367.23 Million
Avg. Volume
1.08 Million
- Currency
- HKD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.8-2.78
- PE
- -
- EPS
- -
- Beta Value
- 0.209
- ISIN
- KYG2588M1006
- CUSIP
- G2588M100
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jianxin Yang M.D., Ph.D.
- Employee Count
- -
- Website
- https://www.cstonepharma.com
- Ipo Date
- 2019-02-26
- Details
- CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.
More Stocks
-
4931
-
CKPT
-
CASY
-
0J9PIncyte Corporation
0J9P
-
LB
-
ITERAItera ASA
ITERA
-
PMT-PC
-
IAM